A Feasibility Study of Oral Adjuvant Chemotherapy With S-1
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The investigators confirm the feasibility of 1-year administration of oral fluoropyrimidine
S-1 as an adjuvant chemotherapy for the patient who received complete resection of non-small
cell lung cancer. The investigators presume they can achieve high completion rate with low
toxicity.